The aim of this study is to assess the role of AMH in prediction of poor ovarian response as well as the relation between ESR 2 (+ 1730G>A) (rs4986938) and FSHR p.Thr 307 Ala (c.919A>G, rs6165) SNPs and the poor ovarian response in Egyptian women undergoing IVF procedure. Discovering the genetic variants associated with ovarian response is an important step towards individualized pharmacogenetic protocols of ovarian stimulation.
Introduction
Infertility is the inability to conceive despite of having regular unprotected sexual intercourse for at least 12 months [1] . Worldwide, it affects 15% of couples of reproductive age [2] . In vitro fertilization (IVF) procedures are the reasons behind the occurrence of approximately 2-3% of childbirths in the world's developed countries [2] . The success rate of different assisted reproductive techniques is only about 30% per cycle [3] .
IVF is a complicated process that involves multiple stages [4] . In order to reach the level of success necessary, the number of eggs acquired after the hormonal stimulation should be taken into account. The major and vital problem facing the patients known as Bpoor responders^is the insufficient number of eggs retrieved, resulting in the decrease of oocyte production, cycle cancellation and a significantly lower probability of pregnancy compared to normal responders [5] .
Predicting ovarian response before starting hormonal stimulation is the only way to administer an efficient and safe treatment. The most important predictors of the ovarian response to hormonal stimulation are age, biochemical parameters as basal follicle-stimulating hormone (FSH) levels, serum anti-Mullerian hormone (AMH) and morphological characteristics as antral follicular count (AFC).
Both AFC and AMH were positively and strongly correlated [6] . However, there are concerns about the performance of the AMH assay under different conditions regarding storage of samples and handling techniques [7] .
Genetic variability is also considered as an important factor. Practices of pharmacogenetics to ovarian response could predict stimulation success and could help in regulating, modifying and designing the doses to suit the treatment [8] . Estrogen receptor genes (ESRs) are of great significance in the ovarian response to exogenous FSH due to the effect of estrogen on follicle growth, maturation and oocyte release. Two subtypes of ERs have been identified in humans, ERα and ERβ, encoded by ESR 1 (6q25.1) and ESR 2 (14q23.2) genes, respectively. The genetic availability of ESRs is important for improvements in the diagnosis and treatment of infertility [9] . ESR 2 (+ 1730G>A) (rs4986938) polymorphism inflects the IVF outcome by affecting the number of mature oocytes [4] .
The FSH receptor gene is treated as the primary candidate gene in explaining the differences in controlled ovarian hyperstimulation (COH) results. As FSH exerts its stimulatory effect by binding to its receptor (FSHR), the efficiency of the FSH dose given to a patient is greatly related to the success of COH [10] . The FSHR gene is located at chromosome region 2p21, and consists of ten exons and nine introns [11] . Several single nucleotide polymorphisms (SNPs) in the FSHR gene have been identified; however, only minority of them are correlated with ovarian response to FSH such as p.Thr 307 Ala (c.919A>G, rs6165) and p.Asn 680 Ser (c.2039A>G, rs6166) [12] . The aim of this study is to assess the role of AMH in prediction of poor ovarian response and the relation between ESR2 (+ 1730G>A) (rs4986938), FSHR p.Thr 307 Ala (c.919A>G, rs6165) SNPs and the poor response in Egyptian women undergoing IVF procedure.
Materials and methods
From June 2013 to June 2016, 234 couples with unexplained infertility, seeking the first attempt IVF treatment cycle were recruited in AL-Shark Al-Awsat fertility center. Couples fulfilling the following criteria were considered eligible for participation: women at or under the age of 35 years, with normal thyroid-stimulating hormone and prolactin levels, normal ovulatory cycles (25-35 interval days), together with proven patent fallopian tubes at hysterosalpingography or laparoscopy done within 6 months preceding the IVF cycle, absence of abnormal pelvic pathology or congenital anomalies and presence of both ovaries with normal findings as assessed by trans-vaginal ultrasound and laparoscopy. All male partners had a normal semen analysis according to WHO criteria (WHO 2010), done within 6 months preceding the IVF cycle. All participants had a thorough history taken, physical examination and further evaluation in the form of basal FSH, basal E 2 and AMH levels done at the second day of a spontaneous cycle within 3 months proceeding the IVF cycle. FSH, E2 and AMH levels were measured by enzyme-linked immunosorbent assay (ELISA).
The number of women who met our preselected inclusion criteria was 216. We excluded candidates with chronic medical disorders such as diabetes, previous inadequate response to ovulation induction, biochemical or ultrasound evidence of polycystic ovary syndrome, had performed ovarian surgery and cases of endometriosis diagnosed by laparoscopy or suspected by ultrasound or CA-125 assay.
Our research protocol was approved by the research ethics committee for experimental and clinical studies at Faculty of Pharmacy Cairo University, Cairo, Egypt (BC 705) and a written consent was obtained from all participating couples. The authors confirm that all ongoing and related trials for this drug/intervention are registered (ClinicalTrials.gov ID: NCT02640976). Neither the participants nor those administering the interventions were blinded to study condition assignment.
Ovarian stimulation was performed according to the gonadotropin releasing hormone (GnRH) antagonist protocol with a fixed daily morning dose of human menopausal gonadotropin (HMG) [Merional® 75 IU ampoules, IBSA institute] intra-muscular injection starting on cycle day 2. Based on the patient's body mass index (BMI) and hormonal profile, the daily dose of HMG was adjusted to (225 IU) for participants with AMH levels > 1.5 ng/ml and/or FSH levels ≤ 8 mIU/ml and to (300 IU) for participants with AMH levels < 1.5 ng/ml and/or FSH levels > 8 mIU/ml, doses were increased by 75 IU in cases with BMI > 30 kg/m 2 . On day 2 of the menstrual cycle, the dose of HMG was commenced for all patients and was maintained for 9-15 days according to each participant individual ovarian r es p on s e as s es s ed b y tr an s -v a g i n a l u l t ra s ou n d folliculometry starting on cycle day 7 and continued every other day until the day of human chorionic gonadotropin (hCG) injection. On cycle day 7, the GnRH antagonist Cetrorelix 0.25 mg [Cetrotide® 0.25 mg syringes, Merck Serono] was introduced as daily subcutaneous injections and continued till the day of ovulation triggering. Finally, when at least two follicles reached 17 mm in diameter, ovulation was triggered by a single intra-muscular injection of 10,000 IU of hCG [Choriomon® 5000 IU ampoules, IBSA institut]. Thirty-six hours later, oocyte retrieval was performed and was guided by transvaginal ultrasound.
According to our primary outcome, the number of oocytes collected, patients were classified as poor responders (four oocytes or less) and were considered as good responders if they produced five or more oocytes. The good responders group served as the control group.
Peripheral blood was collected from each patient in an EDTA-containing tube. Genomic DNA was extracted from lymphocytes of peripheral blood by fully automated system of QIAcube using QIAamp DNA Blood Mini Kit (250) plus QIAamp DNA Blood Mini Accessory Set B, cat. no. 1043369. Detection of the polymorphisms ESR2 (+ 1730G>A) (rs4986938) and FSHR p.Thr307Ala (c.919A>G, rs6165) SNPs was performed using the TaqMan system by real-time polymerase chain reaction (PCR). Primers and probes were provided as a readymade assay by Applied Biosystems, Life Technologies. cat. no. 4351379. Assays were performed with TaqMan Universal Master Mix with 20 ng of DNA per reaction. PCR conditions were holding stage at 95°C for 10 min followed by cycling stage 40 cycles; denaturation step at 95°C for 15 s and annealing and extension step at 60°C for 1 min.
Data were statistically described in terms of mean and standard deviation, for quantitative data and frequencies and relative frequencies for qualitative data. HardyWeinberg (H-W) equilibrium for each polymorphism was tested using the Chi-square test. Comparison of quantitative variables was done using unpaired t test when comparing two categories and ANOVA with post hoc test when comparing more than two categories. For comparing categorical data, chi-square (χ 2 ) test was performed. Exact test was used instead when the expected frequency is less than 5. Genotype and allele frequencies were compared between the poor responder and the control groups using chi-square tests. Odds ratio (OR) with 95% confidence intervals was calculated. A probability value (P value) less than 0.05 was considered statistically significant. All statistical calculations were done using SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) version 22.
For each genotype, the respective proportions were compared in a Stat view program (SAS institute) using Chi-2 and Fisher tests. The family wise error rate was adjusted with the sequential Bonferroni-Holm procedure.
Results
A total of 216 women, who met our preselected inclusion criteria, were included in this study, 111 were classified as good responders and 105 as poor responders. None of them were lost to follow up and they all were analysed in our results.
There was no significant difference between the two groups regarding age, BMI, duration of infertility, basal E2 and endometrial thickness at triggering but a highly significant higher FSH basal level and lower AMH levels among poor responders when compared with good responders (Table 1) .
There was a highly significant difference between the two study groups regarding duration of stimulation, total dose of gonadotropins used, number of oocytes retrieved, number of embryos transferred and clinical pregnancy rate (Table 1) .
Basal FSH, the total dose of gonadotropins used and duration of stimulation, were significantly lower in the good responders group. The number of oocytes retrieved, the number of embryos transferred as well as clinical pregnancy rate were significantly lower in the poor responders group (Table 1) .
To nullify the effect of number of transferred embryos, we compared good responders who transferred one embryo with those poor responders who transferred one embryo. The clinical pregnancy rate was significantly higher in good responders [17/40 (42.5%)] when compared to poor responders [26/92 (28.3%)] (P < 0.001).
The genotype distribution and allelic frequency of both SNPs are summarized on Table 2 . Genotype frequencies observed during this study followed Hardy-Weinberg equilibrium.
Studying the ESR 2 gene polymorphism, we observed a significant difference in the frequency of genotypes between the good and poor responder groups; the genotype AA was three-fold higher in the poor responders group than in the good responders group. The wild genotype GG was 1.98-fold higher in the good responders group and allele G was 1.4-fold higher in the good responders group while allele A was 1.6-fold higher in the poor responders group (Table 2) .
Regarding the FSHR Thr 307 Ala gene polymorphism, there was a significant difference in the frequency of genotypes between the good and poor responders group, the genotype GG (Ala 307 Ala) was 2.5-fold higher in the poor responders group than in the good responders group. The wild genotype AA (Thr 307 Thr) was 2.8-fold higher in the good responders. Allele A was more common in the good responders group. On the other hand, allele G was 1.6-fold higher in the poor responders group (Table 2) .
Regarding the association between ESR 2 genotypes and the patients' baseline characteristics, the mean AMH level and the number of oocytes were significantly higher in the GG and the GA genotypes than in the AA genotype in good responders (Table 3 ). The mean number of oocytes was significantly lower in the AA genotype than in the GA genotype and in the GG genotype and the mean AMH level was significantly higher in the GG genotype than in the GA genotype and in the AA genotype in poor responders (Table 3) .
Studying the association between the FSHR p.Thr 307 Ala genotypes and the patients' baseline characteristics, the mean age was significantly higher in the AA genotype than in the AG and GG genotype. The AMH level and the number of oocytes was significantly higher in the AA genotype than the AG and the GG genotypes in good responders ( Table 4 ). The mean age was significantly higher in the AA genotype than in the AG and GG genotype and the mean number of oocytes was significantly lower in the AG genotype than in the AA and GG genotype in poor responders group (Table 4) .
Our results showed in Table 4 , in the poor responders group of FSHR gene polymorphism, that there was no significant difference in AMH level between the three genotypes, although there was a significant difference in number of oocytes. Therefore, the genetic testing could be a better predictor of poor ovarian response, even though it is of higher cost than other markers, since it offers a possibility to proceed with a personalized approach in IVF, which reduces the incidences of treatment cancellations and complications and lowers the number of treatment cycles required to achieve pregnancy.
In a combined analysis, we observed that the most common diplotype was (A/G + G/A) (24.3%) in the good responders group and (A/G + A/A) (26.7%) in the poor responders group, as shown in Table 5 .
Discussion
To the best of our knowledge, in Egypt, we are the first to demonstrate that the ESR2 (+ 1730G>A) (rs4986938) and FSHR p.Thr 307 Ala (c.919A>G, rs6165) SNPs were associated with poor ovarian response to FSH stimulation in Egyptian women undergoing IVF. It is also of importance to note that, although there are studies that associate these SNPs with different disorders, there are also studies which do not provide such evidence, even for the same disease since the haploblock structure and the linkage disequilibrium vary between different populations. Our clinical study observed that the AMH level was a good predictor of poor ovarian response. The mean AMH level was significantly higher in the good responders group than in the poor responders group. There was also a significant difference between the mean AMH level and the genotypes of the ESR2 SNP in both groups: good responders and poor responders, being significantly lower in the AA genotype. Furthermore, in the good responders group, the AA genotype was significantly associated with higher AMH level in FSHR SNP. However, no difference was observed between the mean AMH level and the genotypes of the FSHR SNP in the poor responders group.
Our results were in agreement with Gleicher et al. [13] . AMH has been recognized recently in a meta-analysis as a good predictor of poor ovarian response to ovarian stimulation [14] . Furthermore, Vaze-Parab et al. in 2014 illustrated that the low serum AMH levels and the poor ovarian response in IVF cycles are highly interconnected (AMH value in poor responders was 1.20 ng/ml and in good responders it was 3.38 ng/ml and the difference was statistically significant (P < 0.05)). It was also correlated with high baseline FSH levels, low AFC, low pregnancy rates and high cycle cancellation rate [15] .
Apart from these parameters, another aspect for determining the ovarian response in COH and IVF is the genetic variability by which changes in the human genome could occur that will change cellular and tissue effects of FSH, leading to a change in COH response [10] .
The present study demonstrated that the AA genotype of the ESR2 (+ 1730G>A) (rs4986938) polymorphism was threefold higher in the poor responders group than in the good responders group, while the GA genotype was significantly lower in the poor responders group. Therefore, the presence of allele A increased the frequency of poor ovarian response. On the other hand, the genotype GG was twofold higher in the good responders group. Moreover, the poor responders had significantly higher basal FSH, required higher doses of FSH for COH, and were associated with lower oocyte yield; also, the AA genotype was significantly associated with lower oocyte yield compared with the other genotypes in both groups.
Our findings were in agreement with Boudjenah et al. who published a study in 2012 performed on 427 women and included 13 SNPs that reportedly influence the outcome of IVF. They have demonstrated that women who were homozygous for the G allele had a greater oocyte yield than women who were heterozygous for the A allele (8.1 ± 4.2 vs. 7.2 ± 4.0, respectively; P = 0.0017) or group of women who were homozygous for the A allele (7.2 ± 3.9; P = 0.0314). Moreover, they observed that in order to achieve a similar oocyte count, higher FSH doses were given for women who were homozygous for the A allele than women who were homozygous or heterozygous for the G allele. Their results implement that the IVF outcome is modulated by the ESR2 (+ 1730G>A) gene polymorphism by affecting the number of mature oocytes [4] . Similarly, De Mattos et al. reported a statistical relation between the GG genotype and better COH outcome [9] .
Nowadays, there appears to be only two polymorphisms with positive reliable predictive value that are suitable for assessing the required rFSH dosage in COH in clinical tests, which are FSHR Thr 307 Ala and Asn 680 Ser polymorphisms [16] .
Our study showed the relation between FSHR Thr 307 Ala polymorphism and ovarian response to COH. We observed that the GG (Ala 307 Ala) was significantly associated with higher frequency of poor ovarian response; it was threefold higher in the poor responders group; however, the genotype AG was significantly decreased in the poor responders group and the genotype AA (Thr 307 Thr) was 2.8-fold higher in the good responders group. Therefore, the presence of Allele G significantly increased the frequency of the poor ovarian response. Our results were in accordance with Rod et al. who noticed that position 307 of the FSHR SNP was more representative than position 680 of SNP. Seventy women from Caen (France) and Byalistok (Poland) undergoing IVF treatment participated in his study. The oocyte yield was significantly different (P < 0.001) between the good responders and the poor responders (11.46 ± 3.5 and 2.67 ± 1.2 respectively). A significant difference was reported in the frequency of genotypes between the good responders and poor responders, with a higher frequency of the genotype combination Ala 307 Ala/Ser 680 Ser in the poor responders group. This difference was greater for variant 307 (P = 0.012), for which the Ala 307 Ala genotype was three times as frequent in poor responders as in good responders. As a result, the Ala 307 Ala genotype increased the risk of poor ovarian response to FSH stimulation [12] .
They were also in agreement with Achyuta et al. who confirmed that women with the Ala 307 variant were associated with reduced COH outcomes as well as lower pregnancy rates. These women had higher basal FSH serum concentrations and required higher doses of FSH for COH [15] .
One of the interesting finding in our study was the significantly higher age within AA genotype when compared to AG and GG genotypes among both good and poor responders. The explanation of that is not known and never observed by previous researchers. However, that could be related to different fertility potential among different genomic expression and consequently different age of presentation for infertility and IVF treatment.
Unexpectedly, reports arose of which the association of the Ala 307 allele with high response rather than low response emerged opposes the general findings [4, 16] .
Our study is limited by a non-randomized clinical trial according to good and poor responders in order not to decrease the possibility of pregnancy rate for poor responders if accidentally randomized into the lower dose protocol of the good responders. Furthermore, not reporting the quality of follicles and/or oocytes is also a limitation to our study.
The clinical implications of the previous findings are highly important; for the final goal, in order to predict the ovarian response, the genetic markers can be considered before the ovarian stimulation. An important step ahead could be expressed in applying this for not only identifying the poor responders' patients as well as modifying the amount of FSH used in IVF protocols according to their genetic background but also, for identifying the most suitable management strategy, developing the chances of a strong outcome and sidestepping the obstacles related to the FSH stimulation. However, its routine use is limited by its costs. 
